finanzen.net

MANNKIND - 2013 endlich zum Überflieger?

Seite 1 von 76
neuester Beitrag: 20.03.19 21:31
eröffnet am: 14.02.13 23:07 von: Oki-Wan 2.0 Anzahl Beiträge: 1888
neuester Beitrag: 20.03.19 21:31 von: martin30sm Leser gesamt: 269942
davon Heute: 22
bewertet mit 16 Sternen

Seite: 1 | 2 | 3 | 4 |
74 | 75 | 76 | 76   

14.02.13 23:07
16

617 Postings, 3239 Tage Oki-Wan 2.0MANNKIND - 2013 endlich zum Überflieger?

Alle Anzeichen sprechen dafür, dass MannKind 2013 mit den erwarteten Phase III-Ergebnissen für Afrezza den Durchbruch schafft und das langersehnte FDA-Approval bekommt.
Für MannKind wäre es der Meilenstein schlechthin und durch die daraus erwirtschafteten Revenues würden auch die restlichen Pipelines einen riesigen Schub erfahren.
Soviel steht fest: es wird ein heisser Sommer und die kommenden Monate dürfte MannKind stark zulegen, wie es auch bei anderen Biotech-Schmieden kurz vor Phase III-Resultaten oft der Fall ist.
Zur weiteren Lektüre empfehle ich einen Blick hierauf:
1.
http://www.fool.com/investing/general/2013/02/13/...-to-watch-in.aspx
2.
http://finance.yahoo.com/q?s=MNKD
3.
http://www.nasdaq.com/symbol/mnkd/real-time#.UR1fXqVk6-h
und 4.
http://www.mannkindcorp.com

Beste Grüsse,
Oki-Wan 2.0

P.S.: Dies ist nur eine Anregung zur eigenen Recherche und keine Handelsempfehlung!  
Seite: 1 | 2 | 3 | 4 |
74 | 75 | 76 | 76   
1862 Postings ausgeblendet.

16.10.18 19:04

4106 Postings, 5119 Tage martin30smEndlich mal ein schoener Anstieg

30.10.18 07:04
1

2106 Postings, 3671 Tage MagnetfeldfredyMannkind goes Cannabis

Geil, das könnte mit dem Partner RLS was ganz Großes werden:


Receptor Life Sciences raises $29M, unveils its work on inhaler for medicines based on cannabis

by Clare McGrane on October 29, 2018 at 1:43 pm

Receptor Life Sciences CEO Gregory Wesner. (Lane Powell Photo)

Seattle-based biotech company Receptor Life Sciences announced a $29 million series A funding round Monday as it emerged from stealth mode, unveiling its work on medicines derived from cannabis.

The $29 million is the first time the company has raised funds. Through a spokesperson, it declined to identify its investors.

Arthur Rubinfeld, a longtime executive at Starbucks, is listed as a director of the company in an SEC filing that disclosed the new funding. Rubinfeld left Starbucks, where he was most recently the president of global innovation at the company?s roastery, in 2016. He is also the founder of Airvision, an advisory firm specializing in consumer oriented businesses.

Receptor?s main product is an inhaler that delivers dry powdered medicines directly to a patient?s lungs. The drugs it plans to use are cannabinoid medicines, compounds based on the active constituents in cannabis. Scientists have extracted more than 100 cannabinoids from the plant, all with varied effects on the nervous system.

Receptor is led by CEO Gregory Wesner, a lawyer who is the chair of intellectual property litigation for Seattle law firm Lane Powell. It currently has five employees.

In a press release, Wesner said the series A will allow the company to start moving through the investigational new drug process with the Food and Drug Administration in the U.S., a step needed before the technology could launch to the market. He said it will also let the company formalize collaborations in Canada and Europe.

?The growing consensus is that cannabinoids have the potential to meet numerous and significant unmet medical needs for indications including epilepsy, chronic pain and post-traumatic stress disorder,? Wesner added. ?By leveraging validated drug delivery technologies, we believe our products have the potential to set the standard of care for cannabinoid medicines in terms of onset of action, bioavailability and consistency.?

Also on the company?s executive board: Chief Medical Officer Orrin Devinsky, a neurological professor and the director of New York University?s Comprehensive Epilepsy Center; Chief Scientific Officer and longtime biopharmaceutical executive Andrea Leone-Bay, who is an authority on dry powder and oral drug delivery technologies; and startup finance executive Traci Carman, who is the company?s chief financial officer.

Receptor first revealed details of its work in filings submitted during a prolonged appeal with the United States Patent and Trademark Office in its effort to trademark its name. That appeal was rejected on Sept. 29, according to USPTO records.
 

01.11.18 20:07

1312 Postings, 560 Tage FrozenfrogWeiss jemand wann die zahlen kommen?

02.11.18 07:34

1312 Postings, 560 Tage FrozenfrogHier

-Earnings: -$24.17 million in Q3 vs. -$32.89 million in the same period last year. -EPS: -$0.16 in Q3 vs. -$0.31 in the same period last year. -Analysts projected -$0.18 per share -Revenue: $4.47 million in Q3 vs. $2.04 million in the same period last year.
 

13.11.18 12:46

4106 Postings, 5119 Tage martin30smIrgendwie habe ich so ein Gefühl, dass hier bald

die Post ab geht....  

07.12.18 15:44

1312 Postings, 560 Tage FrozenfrogStückzahl passt

08.12.18 09:23

4106 Postings, 5119 Tage martin30smDas wird schon...

10.12.18 07:24

1312 Postings, 560 Tage Frozenfroglangsam kommt

hier wieder Leben rein. Auch die ganzen News auf Stockwits  

20.12.18 11:39

4106 Postings, 5119 Tage martin30sm$40 Millionen Public Offering

MannKind Announces Pricing of $40 Million Public Offering

WESTLAKE VILLAGE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) (MannKind) today announced the pricing of an underwritten public offering of 26,666,667 shares of its common stock and warrants to purchase up to an aggregate of 26,666,667 shares of its common stock.  Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $1.50, for a gross deal size of $40.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses. Each warrant will have an exercise price of $1.60 per share, will be exercisable immediately and will expire on the 12-month anniversary of the date of issuance. The shares of common stock and warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance.  The offering is expected to close on December 26, 2018, subject to customary closing conditions.

Leerink Partners is acting as sole book-running manager for the offering.  BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-lead managers for the offering.  H.C. Wainwright & Co., LLC acted as a financial advisor to MannKind in connection with the offering.

The securities described above are being offered by MannKind pursuant to a shelf registration statement on Form S-3 (No. 333-210792) previously filed by MannKind with the Securities and Exchange Commission (SEC) on April 18, 2016 and declared effective on April 27, 2016. The offering will be made only by means of a written prospectus and prospectus supplement that form part of the registration statement. A preliminary prospectus supplement related to the offering and accompanying prospectus has been filed with the SEC and is available on the SEC website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to the offering, when available, may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: (800) 808-7525, ext. 6132, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature, including statements regarding MannKind?s expectations with respect to its public offering, including the anticipated closing date, are ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as ?believes,? ?anticipates,? ?plans,? ?expects,? ?intends,? ?will,? ?goal,? ?potential? and similar expressions are intended to identify forward-looking statements. These statements are based upon MannKind?s current expectations. Actual events or results could differ materially from those anticipated in such forward-looking statements due to various factors, including market risks and uncertainties and the satisfaction of customary closing conditions for an offering of securities. For a discussion of these and other factors, please refer to MannKind?s quarterly report on Form 10-Q for the quarter ended September 30, 2018 as well as MannKind?s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

MannKind Contact:

Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com

MannkindLogoStackedPreferd.jpg
Source: MannKind  

20.12.18 12:22

1312 Postings, 560 Tage FrozenfrogNicht wirklich

Optimal. Was denkst du?  

20.12.18 12:24

4106 Postings, 5119 Tage martin30smmittelfristig sehe ich das positiv....

04.01.19 10:02

2106 Postings, 3671 Tage MagnetfeldfredyMannkind und Afrezza

Heute CC, mal schauen was unser CEO zu sagen hat!  

17.01.19 15:18

2106 Postings, 3671 Tage MagnetfeldfredyMannkind und Afrezza

Super Werbeaktion, das hilft den Richtigen und wird den Bekanntheitsgrad stark steigern, 65.000 Diabetiker zahlen monatlich cash um ihr Insulin zu erhalten, da könnte für Mannkind ein Stück vom Kuchen drin sein:

MannKind Announces Direct Purchase Insulin Program Providing Afrezza® for as low as $4 a Day
GlobeNewswire?January 16, 2019

More than 65,000 patients currently pay cash for their daily insulin each month

WESTLAKE VILLAGE, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced a direct purchase program to help those with diabetes obtain the company?s inhaled insulin, Afrezza, for as little as $4 a day. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

?It is important for MannKind to help those whose lives depend on insulin, and, unfortunately, over 65,000 uninsured or under-insured patients today must pay cash for their insulin each month, typically at the pharmacy counter at prices that reflect the costs of the pharmaceutical distribution chain,? said Michael Castagna, Chief Executive Officer of MannKind. ?Our new Afrezza Patient Direct Program enables us to streamline the numerous costs and inefficiencies that exist in today?s healthcare system, so we can pass along the savings directly for these patients. We want to be part of the solution for the future of healthcare and healthy living.?

Participation in this innovative cash program, which is available to all eligible patients with a valid prescription, is simple. The first 1,000 people to register at www.insulinsavings.com will gain access to introductory pricing for the Afrezza Patient Direct Program, giving them the opportunity to purchase Afrezza for as little as $4 a day for the first twelve months. All participants who sign up for the program will gain access to attractive cash pricing for Afrezza.

Additional program information is available online at www.insulinsavings.com. Patients who would like to enroll should click the ?Register Now? button and follow the instructions. MannKind has partnered with Eagle Pharmacy to process patients? prescriptions and to ship Afrezza directly to their home. Payment is made using any major credit card.

MannKind has also launched an enhanced copay and savings card program that will enable patients with commercial insurance to fill their prescription at their local pharmacy for as low as $15. The card, along with complete program details, can be downloaded at www.afrezzasavingscard.com.

?Our founder Al Mann had a vision of making Afrezza available to all people living with diabetes, and it?s concerning that rising costs may cause some with diabetes to go without insulin,? Castagna said. ?We hope that our new programs will have an impact and help many in need.?

About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.  Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration.  Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels.  For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.

About MannKind Corporation
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC. For a discussion of these and other factors, please refer to MannKind?s quarterly report on Form 10-Q for the quarter ended September 30, 2018 as well as MannKind?s other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Contact:

Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com

Contact:

 

18.01.19 11:42

3158 Postings, 647 Tage VassagoMNKD 1,39$

massives Cash und Verwässerungsproblem

  • Cashbestand nach Q3/18 ~11 Mio. $
  • Kapitalerhöhung 12/18 (~40 Mio. $ / 26,66 Mio. Stück zu 1,50$)
  • Cashbestand neu: ~51 Mio. $
  • Verlust in Q3/18 ~24 Mio. $
  • Verlust nach 9 Monaten ~77 Mio. $
  • bei den Zahlen reicht das Cash nur ca. 2 Quartale (Q4/18 und Q1/19) bis zur nächsten Kapitalerhöhung und Verwässerung
  • hohe Verschuldung
  • negatives Eigenkapital

http://investors.mannkindcorp.com/news-releases/...-quarter-financial

 

12.02.19 16:11

4106 Postings, 5119 Tage martin30smJetzt kommt endlich Bewegung rein....

21.02.19 07:01

2106 Postings, 3671 Tage MagnetfeldfredyMannkind und Afrezza

MannKind Presents New Scientific Data at 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
GlobeNewswire?February 20, 2019

WESTLAKE VILLAGE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced additional positive Afrezza clinical data to be presented in an oral presentation on Thursday, February 21, 2019 and a poster on Wednesday, February 20, 2019 at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019).

?The data to be presented provide additional insight into the pharmacodynamic effects produced by the ultra-rapid pharmacokinetic profile of inhaled Afrezza insulin compared to those associated with subcutaneous rapid acting insulin,? stated Dr. David Kendall, Chief Medical Officer of MannKind. ?By delivering a time-action profile closer to that of physiologic insulin action, post-prandial glucose levels and other markers of glycemic control were significantly improved compared to injected insulin in meal-challenge tests in patients with type 2 diabetes.?  

Other data presented at this meeting showed that the pulmonary function of patients with diabetes is more impacted by factors such as high body mass index, elevated HbA1c levels and the time since onset of diabetes than by the effect of inhaled insulin.  Kendall added ?we believe that these and other recently published data significantly advance our understanding of the treatment opportunity that Afrezza therapy can offer.?
Oral Presentation Highlights

Title:   Ultra-rapid profile of insulin human inhalation powder mimics time-action profile of physiologic absorption of glucose from mixed-meal tolerance tests in type 2 diabetes
ATTD 2019 Thursday, February 21st (Hall M4): 17:20-17:30
   
Presenter:   Marshall Grant, Senior Director, Head of Pharmaceutical Research, MannKind Corporation
   
Description:   This analysis was based on a randomized cross-over mixed-meal tolerance test study in type 2 diabetes and conducted to determine how the ultra-rapid PK/PD profile of Afrezza affects various facets of glucose control
   
Highlights:   Compared to subcutaneous rapid-acting insulin, the ultra-rapid PK profile of Afrezza resulted in:

   reduced glucagon exposure by 30-35%
   reduced C-peptide exposure out to 3 hours
   better early post-prandial glucose control
   a longer period of tight glucose control with higher doses of Afrezza
   earlier reductions in free fatty acids and endogenous glucose production

Poster Presentation Highlights
   
Title:   Diabetes Duration, BMI, and HbA1c Have Greater Effects on Pulmonary Function (PF) Than Inhaled Technosphere® Insulin (Encore, previously presented at EASD)
ATTD 2019 Wednesday, February 20th (poster presentation Friday, February 22nd 10:20-10:25 Exhibition Area)
   
Presenter:   Frank Pompilio, PharmD, VP, Medical Affairs, MannKind Corporation
   
Description:   Data from a pulmonary function (PF) study of patients with type 1 and type 2 diabetes was utilized to compare the effects of diabetes duration, body mass index (BMI), and HbA1c on baseline PF and changes in PF during 24 months of treatment between patients receiving Afrezza and those receiving usual care.
   
Highlights:   The magnitude of Afrezza?s effect on FEV1 was comparable to those normally associated with diabetes-related factors such as high BMI, elevated HbA1c and long-standing diabetes

   No effects were clinically significant
   Afrezza-related decreases in FEV1 were small, non-progressive and reversible after two years of treatment

About ATTD Annual Meeting
The ATTD is a scientific program that brings leading international experts together to discuss breakthroughs in diabetes treatments, technological innovations and showcase the latest developments in new insulin analogues, delivery systems, pumps, glucose sensors, closed-loop systems and much more.

About Afrezza®
Available by prescription, Afrezza® (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.  Afrezza consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. Administered at the beginning of a meal, Afrezza dissolves rapidly upon inhalation to the lung and passes quickly into the bloodstream (in less than one minute). This rapid absorption allows Afrezza to begin reducing blood sugar levels within about 12 minutes of administration.  Afrezza is available in 4-unit, 8-unit and 12-unit single-dose cartridges of insulin powder that can be used, as prescribed by a health care professional, in combination with other diabetes medications to achieve target blood sugar levels.  For Afrezza doses exceeding 12 units, patients may use a combination of existing cartridge strengths. For more information on Afrezza, please visit www.afrezza.com.

About MannKind
MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties.  Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties detailed in MannKind's filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

MannKind Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com

Contact:

 

26.02.19 21:00

4106 Postings, 5119 Tage martin30smWas ist bei Mannkind ploetzlich los?

Gibt es News? Warum gibt es ploetzlich einen Anstieg?  

26.02.19 21:37
1

1312 Postings, 560 Tage FrozenfrogWeil die Quartalszahlen

Super sind.  

13.03.19 10:10

4106 Postings, 5119 Tage martin30smSo kann es weitergehen.... Schöner

Kursverlauf in den letzten Wochen :-)  

13.03.19 15:21

4106 Postings, 5119 Tage martin30smUnglaublich wie MNKD abgeht....

15.03.19 07:28

4106 Postings, 5119 Tage martin30smMNKD to Sponsor Andretti Autosport

MannKind to Sponsor Andretti Autosport Type 1 Diabetes Driver, Conor Daly
IndyCar Driver Living with Diabetes Helps Raise Awareness for Diabetes Treatment Options

WESTLAKE VILLAGE, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) announced today it is sponsoring Conor Daly as he makes his debut with the Andretti Autosport team at the 103rd Running of the Indianapolis 500 on May 26, 2019. MannKind is an associate sponsor of Andretti Autosport for this race and will partner with Daly on his No. 25 U.S. Air Force Honda. Daly was diagnosed with Type 1 diabetes at the age of 14, and now lends his racing career to raise awareness of diabetes treatment options and innovations.

?Living with diabetes since age 14 has been a challenge, but one that I?ve always faced head on,? said Daly. ?Managing my diabetes properly has been a key to being able to live my racing dream.  Diabetes should never stop you from pursuing what you want in life!  Thanks to MannKind I will be able to share my story and live my dream at a higher level than ever."

?MannKind is continually seeking platforms to increase awareness around the challenges, opportunities and successes people living with diabetes encounter on a daily basis,? says Michael Castagna, CEO of MannKind. ?Seeing someone like Conor take on a challenging sport such as IndyCar racing, while having to manage his diabetes, is an inspiration to all those living with diabetes. We are excited to be associated with Conor and Andretti Autosport for the Indy 500 and look forward to a partnership where we can help educate people on treatment options for managing their diabetes.?

As an associate sponsor of Daly at the Indy 500, MannKind is planning events and experiences that build awareness of innovation in diabetes treatment.  The events and sponsorship promotion will also allow for Daly to share his story about living with diabetes.

About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing and research facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

About Andretti Autosport
Led by racing legend Michael Andretti, Andretti Autosport boasts a wide racing portfolio rooted in tradition and designed for success.

Under the banners of Andretti Autosport, Andretti Rallycross and Andretti Formula E, the Indianapolis-based team fields multiple entries across the IndyCar Series, Indy Lights, the FIA Formula E Championship, the GT4 America Series and Americas Rallycross. Additionally, the team competes as Walkinshaw Andretti United in the Australian Supercars category through partnership with Walkinshaw Racing and United Autosports.

The global racing enterprise boasts four IndyCar Series championships, three Indy Lights titles, one Pro Mazda championship and one USF2000 championship, and has captured victory five times at the famed Indianapolis 500-Mile Race. Additionally, the team holds two X Games Gold Medals and four U.S. rallycross championships.

To share in the Andretti story, please visit online at AndrettiAutosport.com and follow along on social media with #AllAndretti.

Company Contact:
Rose Alinaya
SVP, Investor Relations
818-661-5000
ir@mannkindcorp.com

MannkindLogoStackedPreferd.jpg
Source: MannKind  

20.03.19 15:07
1

319 Postings, 742 Tage RogerFÜber 2,30$

zu schließen, wäre Charttechnisch ein Traum  

20.03.19 15:40

1312 Postings, 560 Tage FrozenfrogWerden wir

20.03.19 21:31

4106 Postings, 5119 Tage martin30smHeute leider nicht, dafür dann morgen....

Seite: 1 | 2 | 3 | 4 |
74 | 75 | 76 | 76   
   Antwort einfügen - nach oben
finanzen.net Brokerage

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
BayerBAY001
Deutsche Bank AG514000
CommerzbankCBK100
Apple Inc.865985
Amazon906866
Daimler AG710000
Aurora Cannabis IncA12GS7
Deutsche Telekom AG555750
BASFBASF11
SteinhoffA14XB9
NEL ASAA0B733
Allianz840400
TeslaA1CX3T
Siemens AG723610